GVAG
ELVN icon

Great Valley Advisor Group’s Enliven Therapeutics ELVN Stock Holding History

Great Valley Advisor Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,415
Closed -$55.9K – 721
2022
Q4 		$55.9K Sell
3,415
-1,838
-35% -$29.4K ﹤0.01% 675
2022
Q3 		$48K Hold
5,253
– – ﹤0.01% 656
2022
Q2 		$26K Hold
5,253
– – ﹤0.01% 659
2022
Q1 		$40K Sell
5,253
-400
-7% -$2.64K ﹤0.01% 579
2021
Q4 		$51K Sell
5,653
-1,200
-18% -$15.7K ﹤0.01% 585
2021
Q3 		$112K Sell
6,853
-1,200
-15% -$24.9K 0.01% 561
2021
Q2 		$254K Buy
+8,053
New +$250K 0.02% 484

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Great Valley Advisor Group's ELVN Position: Q1 2023 in Review

Great Valley Advisor Group sold out of Enliven Therapeutics (ELVN) in Q1 2023, closing a stake of 3,415 shares — an estimated $55.9K sold.

Great Valley Advisor Group first reported a position in ELVN in Q2 2021 and held it in 7 quarters. The position peaked at $254K in Q2 2021. 45 funds tracked by Wall St. Rank hold ELVN as of Q1 2023.

  • Great Valley Advisor Group reported no remaining Enliven Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Great Valley Advisor Group sold 3,415 Enliven Therapeutics shares in Q1 2023, an estimated $55.9K.
  • Great Valley Advisor Group first reported a position in Enliven Therapeutics in Q2 2021 and held it in 7 quarters.
  • Great Valley Advisor Group's Enliven Therapeutics position peaked at $254K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2023.

Based on Great Valley Advisor Group's 13F filing for Q1 2023, filed 3 May 2023.